Blood Transfusion Reactions—A Comprehensive Review of the Literature including a Swiss Perspective

Author:

Ackfeld TheresaORCID,Schmutz Thomas,Guechi Youcef,Le Terrier ChristopheORCID

Abstract

Blood transfusions have been the cornerstone of life support since the introduction of the ABO classification in the 20th century. The physiologic goal is to restore adequate tissue oxygenation when the demand exceeds the offer. Although it can be a life-saving therapy, blood transfusions can lead to serious adverse effects, and it is essential that physicians remain up to date with the current literature and are aware of the pathophysiology, initial management and risks of each type of transfusion reaction. We aim to provide a structured overview of the pathophysiology, clinical presentation, diagnostic approach and management of acute transfusion reactions based on the literature available in 2022. The numbers of blood transfusions, transfusion reactions and the reporting rate of transfusion reactions differ between countries in Europe. The most frequent transfusion reactions in 2020 were alloimmunizations, febrile non-hemolytic transfusion reactions and allergic transfusion reactions. Transfusion-related acute lung injury, transfusion-associated circulatory overload and septic transfusion reactions were less frequent. Furthermore, the COVID-19 pandemic has challenged the healthcare system with decreasing blood donations and blood supplies, as well as rising concerns within the medical community but also in patients about blood safety and transfusion reactions in COVID-19 patients. The best way to prevent transfusion reactions is to avoid unnecessary blood transfusions and maintain a transfusion-restrictive strategy. Any symptom occurring within 24 h of a blood transfusion should be considered a transfusion reaction and referred to the hemovigilance reporting system. The initial management of blood transfusion reactions requires early identification, immediate interruption of the transfusion, early consultation of the hematologic and ICU departments and fluid resuscitation.

Publisher

MDPI AG

Subject

General Medicine

Reference114 articles.

1. Analyse des Annonces D’hémovigilancehttps://www.swissmedic.ch/swissmedic/fr/home/humanarzneimittel/marktueberwachung/haemovigilance/haemovigilance-publications-events/haemovigilance-report-2020.html

2. The Swiss Haemovigilance Reporting System—Fundamentals. Swissmedic-Analyse des Annonces D’hémovigilancehttps://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/haemovigilance/haemovigilance-publications-events.html

3. The Swiss Haemovigilance Reporting System—Fundamentals. Swissmedic-Analyse des Annonces D’hémovigilancehttps://www.swissmedic.ch/swissmedic/de/home/humanarzneimittel/marktueberwachung/haemovigilance/haemovigilance-publications-events.html

4. https://ansm.sante.fr/uploads/2021/12/08/20211208-rapport-hemovigilance-2020-vf.pdf

5. Hämovigilanz-Bericht des Paul-Ehrlich-Instituts 2020: Auswertung der Meldungen von Reaktionen und Zwischenfällen nach § 63i AMGwww.pei.de/haemovigilanzbericht

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3